Lilly’s Retevmo boosts event-free survival in early-stage NSCLC
Eli Lilly’s Retevmo met its primary endpoint of event-free survival in patients with early-stage NSCLC.
17 February 2026
17 February 2026
Eli Lilly’s Retevmo met its primary endpoint of event-free survival in patients with early-stage NSCLC.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.